BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33819295)

  • 1. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
    PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
    Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
    Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
    J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.
    Ullrich T; Quentin M; Arsov C; Laqua N; Abrar D; Hiester A; Albers P; Antoch G; Schimmöller L
    Rofo; 2020 May; 192(5):441-447. PubMed ID: 31622990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
    Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
    J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 9. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 11. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: A diagnostic accuracy study.
    Cosma I; Tennstedt-Schenk C; Winzler S; Psychogios MN; Pfeil A; Teichgraeber U; Malich A; Papageorgiou I
    PLoS One; 2019; 14(12):e0227031. PubMed ID: 31869380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.
    Prabhu V; Rosenkrantz AB; Otazo R; Sodickson DK; Kang SK
    J Magn Reson Imaging; 2019 May; 49(5):1400-1408. PubMed ID: 30629317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
    Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
    Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
    Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
    Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.
    Schimmöller L; Quentin M; Arsov C; Hiester A; Buchbender C; Rabenalt R; Albers P; Antoch G; Blondin D
    Eur Radiol; 2014 Oct; 24(10):2582-9. PubMed ID: 24972954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
    Afshari Mirak S; Mohammadian Bajgiran A; Sung K; Asvadi NH; Markovic D; Felker ER; Lu D; Sisk A; Reiter RE; Raman SS
    Abdom Radiol (NY); 2020 Jul; 45(7):2225-2234. PubMed ID: 31549211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
    Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.